US Patent 11,053,214: Claim Scope, Exclusivity, Orange Book Status, and Generic Entry Risk
US Patent 11,053,214 covers a specific crystalline dihydrate, Form D, of the hemisuccinate salt of a trifluorobenzamide CGRP-receptor antagonist. Its strongest protection is directed to the identified solid form and its X-ray diffraction profile. The patent also covers pharmaceutical compositions, a wet-granulation production route, and migraine treatment using the claimed form. It does not, based on the supplied claims, claim the underlying free-base compound broadly, all salts, all polymorphs, or every method of treating migraine with the active ingredient.
What compound and drug form does US 11,053,214 protect?
The claimed active pharmaceutical ingredient is the hemisuccinate salt of:
2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]benzamide.
The patent claims the compound as a crystalline Form D dihydrate. The protected material therefore has three defining elements:
- The specified benzamide active ingredient.
- The hemisuccinate salt.
- The Form D crystalline dihydrate.
Removal or alteration of any one of those elements may place a competing product outside claim 1, subject to infringement analysis under the full patent specification and equivalents doctrine.
The supplied claims identify the material by powder X-ray diffraction using Cu-Kα radiation. The required primary peaks are approximately:
| Required peak |
2θ position |
Tolerance |
| Peak 1 |
18.7° |
±0.2° |
| Peak 2 |
26.5° |
±0.2° |
| Peak 3 |
27.0° |
±0.2° |
| Peak 4 |
27.5° |
±0.2° |
| Peak 5 |
27.8° |
±0.2° |
A solid product that contains the same active ingredient and hemisuccinate salt but lacks the claimed Form D diffraction pattern would not literally satisfy claim 1.
What does claim 1 of US 11,053,214 cover?
Claim 1 is an independent product claim to the crystalline Form D dihydrate.
Its practical scope depends on four limitations:
- “crystalline Form D”
- “dihydrate”
- “hemisuccinate salt”
- the specified X-ray diffraction peaks
The X-ray limitation is material. A defendant would likely contest whether the accused material exhibits the required peaks within the stated angular tolerances, whether the peaks are measured under comparable conditions, and whether the diffraction pattern is sufficiently attributable to the claimed form.
The claim does not expressly require:
- a particular particle size;
- a particular morphology;
- a particular solvent system;
- a specified water-content range;
- a specific pharmaceutical excipient;
- a specific dosage strength;
- a particular manufacturing scale; or
- a particular migraine dosing regimen.
The absence of those limitations gives claim 1 potentially broad coverage over commercial quantities of Form D dihydrate, regardless of how the material is manufactured or formulated.
How does claim 2 narrow the crystalline-form protection?
Claim 2 depends on claim 1 and requires one or more additional peaks from the listed diffraction positions.
The additional peak list includes positions ranging from approximately 8.5° to 31.9° 2θ. Because claim 2 requires “at least one or more” selected peaks, it does not require the complete list. A Form D material that satisfies claim 1 and has at least one listed additional peak may fall within claim 2.
Claim 2 provides a secondary identification layer. It may become relevant where a generic manufacturer disputes the reliability of the five primary peaks in claim 1. The longer pattern can support:
- polymorph identification;
- comparison of reference and generic batches;
- quality-control testing;
- infringement testing;
- detection of mixtures of polymorphs; and
- arguments concerning whether a process produces the patented form.
The claim is less restrictive than a claim requiring every listed peak. A product does not need to show the entire 40-position pattern to satisfy claim 2 as written.
What process is protected by claim 3?
Claim 3 covers the dihydrate of claim 1 when it is produced by wet granulation of amorphous Compound I.
This is a product-by-process claim. The accused product must first satisfy the structural requirements inherited from claim 1. The wet-granulation process then supplies an additional limitation.
The claim creates two potential enforcement paths:
- The product has the Form D dihydrate structure and was made by wet granulation of amorphous Compound I.
- The manufacturing process itself may be relevant to proving that the product has the claimed form, even if the process is conducted outside the United States and the finished product is imported into the United States.
Claim 3 is narrower than claim 1 because it requires the specified production history. A competitor using a different process may avoid literal infringement of claim 3 while still infringing claim 1 if its product is the same Form D dihydrate.
The claim also raises evidentiary questions concerning:
- what qualifies as “wet granulation”;
- whether the starting material must be demonstrably amorphous Compound I;
- whether partial wet granulation is sufficient;
- whether solvent-assisted granulation qualifies;
- whether the process must be performed on the active ingredient before formulation; and
- whether the resulting form remains Form D after drying and tableting.
What pharmaceutical compositions are protected by claims 4 through 6?
Claim 4 covers a pharmaceutical composition containing the Form D dihydrate and a pharmaceutically acceptable carrier.
The carrier limitation is broad. It can include conventional excipients used in tablets, capsules, powders, suspensions, or other dosage forms. The claim does not identify a particular excipient or dosage form.
Claim 5 requires the composition to be “substantially free from impurities.” That term would be interpreted in light of the specification, analytical methods, impurity definitions, and technical context. It is not automatically equivalent to a fixed numerical purity threshold.
Claim 6 narrows claim 5 by requiring chemical purity greater than 98.0% as determined by HPLC.
| Claim |
Subject matter |
Principal limitation |
| 4 |
Pharmaceutical composition |
Form D dihydrate plus pharmaceutically acceptable carrier |
| 5 |
Pharmaceutical composition |
Substantially free from impurities |
| 6 |
Pharmaceutical composition |
HPLC chemical purity greater than 98.0% |
Claim 6 is likely relevant to commercial drug substance and finished-dose manufacturing. It may be difficult to enforce without validated analytical testing because the claim depends on the HPLC method, reference standard, sample preparation, detection conditions, and impurity calculation.
Claims 4 through 6 do not expressly require a specific dosage, route, tablet coating, release profile, or indication. A generic formulation containing the claimed solid form could face risk even if its excipient system differs from the originator’s formulation.
What method-of-use protection does claim 7 provide?
Claim 7 covers administering an effective amount of the Form D dihydrate to a human or mammal to treat migraine.
The claim contains the following core limitations:
- a human or mammal in need of treatment;
- migraine as the disease condition;
- administration of an effective amount; and
- administration of the claimed Form D dihydrate.
This is a narrower use claim than a claim covering treatment of all CGRP-mediated disorders. It does not expressly cover cluster headache, general pain, nausea, or other neurological conditions.
The claim may be relevant to a generic product marketed under a label that includes migraine treatment. A generic applicant could seek a section viii “skinny label” that omits the patented migraine indication, but the commercial and inducement analysis would depend on the final label, promotional conduct, prescribing information, and the remaining patent claims. The statutory framework for abbreviated new drug applications and paragraph IV certifications is established under the Hatch-Waxman Act. [2]
When does US 11,053,214 lose exclusivity?
The patent expiration date cannot be established from the claims alone. US patent term generally runs for 20 years from the earliest effective nonprovisional U.S. filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and applicable priority rules. [3]
A reliable expiration analysis requires the patent’s:
- earliest effective priority date;
- U.S. nonprovisional filing date;
- patent-term-adjustment determination;
- terminal-disclaimer status;
- patent-term-extension status; and
- any disclaimer or correction affecting term.
The grant date, June 29, 2021, does not determine the expiration date. A later-issued continuation can expire on the same date as an earlier family member if it claims the benefit of the same priority chain.
What is the Orange Book status of US 11,053,214?
The Orange Book lists patents submitted for approved drug products, including patents covering drug substances, drug products, and approved methods of use. [1]
The supplied claim language does not identify an approved product, NDA number, sponsor, or active ingredient regulatory listing. On that record, an Orange Book listing cannot be assigned conclusively to US 11,053,214.
If the claimed compound has no approved U.S. drug product, the patent would not create a conventional Orange Book-based ANDA barrier. The patent could still be asserted independently against commercial manufacture, importation, sale, or use.
If a related NDA exists, the relevant regulatory questions are:
- whether the hemisuccinate Form D dihydrate is the approved drug substance;
- whether the patent was timely submitted to FDA;
- whether FDA lists it under the drug product;
- whether the listing covers the product, formulation, or method of use; and
- whether an ANDA applicant must file a paragraph IV certification.
FDA does not decide patent validity or infringement when publishing Orange Book listings. Those issues remain subject to litigation. [1]
Does the patent create biosimilar risk?
No conventional biosimilar pathway applies to this patent because the claimed product is a chemically synthesized small molecule rather than a biologic. The relevant competitive pathway would ordinarily be an ANDA for a generic drug, not a biosimilar application under section 351(k) of the Public Health Service Act.
The patent can still create generic risk in four areas:
| Risk area |
Relevance |
| Drug substance |
A generic using the same Form D dihydrate may implicate claim 1 |
| Manufacturing |
Wet granulation of amorphous Compound I may implicate claim 3 |
| Formulation |
A dosage form containing the claimed form may implicate claims 4-6 |
| Labeling and use |
Migraine treatment labeling may implicate claim 7 |
Which companies are challenging US 11,053,214?
The supplied information does not identify any paragraph IV certification, district-court complaint, inter partes review, post-grant review, opposition, settlement agreement, or license involving US 11,053,214.
A patent-number search should distinguish between:
- a paragraph IV certification submitted to FDA;
- a Hatch-Waxman infringement action under 35 U.S.C. §271(e)(2);
- a declaratory-judgment action;
- an inter partes review at the Patent Trial and Appeal Board;
- a reexamination; and
- a validity challenge raised defensively in litigation.
No challenger, filing date, or settlement term should be attributed to this patent without a corresponding public record.
How strong is the patent estate?
The supplied patent has moderate-to-strong protection for the specific solid form but limited apparent breadth beyond it.
Strengths
- Claim 1 is an independent product claim.
- The solid form is identified by multiple X-ray peaks.
- The claim covers the salt and hydration state together.
- Composition claims extend protection into finished pharmaceutical products.
- Claim 7 addresses the commercial migraine indication.
- A competitor may need to change the salt, hydration state, polymorph, or manufacturing route to avoid all claim categories.
Limitations
- The claims do not broadly cover the free-base active ingredient.
- The claims do not expressly cover every salt or polymorph.
- Claim 3 depends on a specific manufacturing history.
- Purity claims depend on analytical methodology.
- Claim 7 may be vulnerable to a carefully drafted indication carve-out.
- The absence of a specified dosage form may create claim-construction disputes, but it also makes the composition claims less tailored to a particular product.
What generic launch scenarios exist?
A generic manufacturer could pursue several strategies:
- Use the same Form D dihydrate. This creates the highest risk under claim 1 and potentially claims 4 through 6.
- Use a different polymorph. This may avoid claim 1 if the alternative does not exhibit the required diffraction pattern.
- Use the free base or another salt. This may avoid the hemisuccinate limitation, subject to other family patents.
- Use a different hydrate or anhydrous form. This may avoid the dihydrate limitation.
- Use a different manufacturing process. This can reduce claim 3 risk but does not avoid claim 1 if the final material is still Form D.
- File a section viii label. This may reduce method-of-use exposure if the relevant migraine indication is carved out and the remaining product claims do not block approval.
The main commercial question is whether other patents in the same family cover the active ingredient, its salts, formulations, methods of treatment, or manufacturing process. US 11,053,214 should therefore be assessed as one layer of a broader family rather than as the complete exclusivity position.
What geographic coverage does the patent provide?
US 11,053,214 provides U.S. patent rights only. It can restrict:
- manufacture in the United States;
- use in the United States;
- sale or offer for sale in the United States;
- importation into the United States; and
- certain conduct connected to an ANDA submission.
It does not directly prevent manufacture, sale, or use in Europe, Japan, China, Canada, or other jurisdictions. Foreign coverage depends on national counterparts, validation, prosecution outcomes, and local expiration dates.
Key Takeaways
- US 11,053,214 primarily protects Form D dihydrate of the hemisuccinate salt.
- The five specified X-ray peaks are central to claim 1.
- Claim 2 adds optional identifying diffraction peaks.
- Claim 3 protects the claimed form made by wet granulation of amorphous Compound I.
- Claims 4 through 6 cover pharmaceutical compositions and a greater-than-98.0% HPLC purity threshold.
- Claim 7 covers migraine treatment using the claimed dihydrate.
- The patent is relevant to generic competition, not biosimilar competition.
- The patent expiration date cannot be derived from the claim text or grant date alone.
- Orange Book and paragraph IV conclusions require a confirmed approved product and associated FDA records.
- The strongest design-around options involve a different polymorph, salt, hydrate state, or active-ingredient form.
FAQs About US Patent 11,053,214
Can a generic use the same active ingredient but a different salt?
Potentially. The claims supplied are directed to the hemisuccinate salt. A different salt may avoid literal infringement, but related patents may separately cover the free base or alternative salts.
Does wet granulation alone infringe claim 3?
No. Claim 3 requires the resulting material to be the Form D dihydrate of claim 1 and requires production by wet granulation of amorphous Compound I.
Does claim 6 require the finished tablet to exceed 98% purity?
The claim requires the pharmaceutical composition to contain the claimed dihydrate having chemical purity greater than 98.0% by HPLC. The applicable interpretation depends on the patent’s analytical method and how purity is measured.
Can an alternative polymorph be used for generic approval?
An alternative polymorph may be technically and legally viable if it does not satisfy the diffraction limitations of claim 1 and is compatible with FDA pharmaceutical-equivalence requirements. Other patents may still restrict that form.
Is Form D protection the same as active-ingredient protection?
No. Form D protection is narrower. It covers the identified crystalline dihydrate and does not, based on the supplied claims, cover every physical form of the active ingredient or every salt of the compound.
References
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application approvals. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
-
United States Patent and Trademark Office. (n.d.). Patent term adjustment. https://www.uspto.gov/patents/laws/patent-term-adjustment
-
United States Patent and Trademark Office. (2021). U.S. Patent No. 11,053,214. https://patents.google.com/patent/US11053214B2/en
